Brooks Laboratories
Brooks Laboratories Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Brooks Laboratories
Start SIPBrooks Laboratories Investment Rating
-
Master Rating:
-
Brooks Laboratories has an operating revenue of Rs. 82.67 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of -26% needs improvement, ROE of -25% is poor and needs improvement. The company has a reasonable debt to equity of 15%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 15 which is a POOR score indicating inconsistency in earnings, a RS Rating of 61 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 95 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|
| Oper Rev Qtr Cr | 16 | 15 | 21 |
| Operating Expenses Qtr Cr | 16 | 19 | 21 |
| Operating Profit Qtr Cr | 0 | -4 | 0 |
| Depreciation Qtr Cr | 0 | 0 | 0 |
| Interest Qtr Cr | 0 | 0 | 0 |
| Tax Qtr Cr | 0 | 0 | 0 |
| Net Profit Qtr Cr | -1 | -5 | 0 |
Brooks Laboratories Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 2
- Bearish Moving Average
- ___
- 14
- 20 Day
- 103.32
- 50 Day
- 106.04
- 100 Day
- 106.65
- 200 Day
- 104.19
- 20 Day
- 101.84
- 50 Day
- 108.57
- 100 Day
- 110.17
- 200 Day
- 101.27
Brooks Laboratories Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 109.19 |
| Second Resistance | 113.62 |
| Third Resistance | 116.14 |
| RSI | 48.01 |
| MFI | 64.33 |
| MACD Single Line | -1.86 |
| MACD | -0.99 |
| Support | |
|---|---|
| First Resistance | 102.24 |
| Second Resistance | 99.72 |
| Third Resistance | 95.29 |
Brooks Laboratories Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 55,334 | 3,350,474 | 60.55 |
| Week | 55,375 | 3,406,658 | 61.52 |
| 1 Month | 33,564 | 2,195,101 | 65.4 |
| 6 Month | 39,232 | 3,475,593 | 88.59 |
Brooks Laboratories Result Highlights
Brooks Laboratories Synopsis
NSE-Medical-Generic Drugs
Brooks Laboratories is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 76.97 Cr. and Equity Capital is Rs. 24.70 Cr. for the Year ended 31/03/2022. Brooks Laboratories Ltd. is a Public Limited Listed company incorporated on 23/01/2002 and has its registered office in the State of Himachal Pradesh, India. Company’s Corporate Identification Number(CIN) is L24232HP2002PLC000267 and registration number is 000267.| Market Cap | 254 |
| Sales | 70 |
| Shares in Float | 0.84 |
| No of funds | 2 |
| Yield |
| Book Value | 3.9 |
| U/D Vol ratio | 0.8 |
| LTDebt / Equity | 2 |
| Alpha | 0.07 |
| Beta | 0.98 |
Brooks Laboratories
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 66.41% | 66.41% | 66.41% | |
| Foreign Portfolio Investors | ||||
| Individual Investors | 27.8% | 28.19% | 28.75% | |
| Others | 5.79% | 5.4% | 4.84% |
Brooks Laboratories Management
| Name | Designation |
|---|---|
| Mr. Atul Ranchal | Chairman |
| Mr. Rajesh Mahajan | Managing Director |
| Mr. Manpreet Singh Naroo | Director - Technical |
| Ms. Sonia Gupta | Independent Director |
| Mr. Deepak Mahajan | Independent Director |
| Mr. Rajnish Kumar Bedi | Independent Director |
Brooks Laboratories Forecast
Price Estimates
Brooks Laboratories Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-02-14 | Quarterly Results | |
| 2023-01-25 | Rights issue of Equity Shares | |
| 2022-11-14 | Quarterly Results | |
| 2022-08-10 | Quarterly Results | |
| 2022-05-30 | Audited Results |
Brooks Laboratories FAQs
What is Share Price of Brooks Laboratories ?
Brooks Laboratories share price is ₹102 As on 05 February, 2023 | 19:38
What is the Market Cap of Brooks Laboratories ?
The Market Cap of Brooks Laboratories is ₹252 Cr As on 05 February, 2023 | 19:38
What is the P/E ratio of Brooks Laboratories ?
The P/E ratio of Brooks Laboratories is -10 As on 05 February, 2023 | 19:38
What is the PB ratio of Brooks Laboratories ?
The PB ratio of Brooks Laboratories is 1.9 As on 05 February, 2023 | 19:38